Ken Griffin Freeline Therapeutics Holdings PLC Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.42 - $0.63 $39,073 - $58,609	93,031 Added 391.48%	116,795 $53,000
Q4 2022 Feb 14, 2023	BUY	$0.46 - $0.73 $10,931 - $17,347	23,764 New	23,764 $11,000
Q3 2021 Nov 15, 2021	SELL	$3.04 - $8.9 $40,216 - $117,738	-13,229 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.15 - $13.9 $107,816 - $183,883	13,229 New	13,229 $107,000
Q4 2020 Feb 16, 2021	SELL	$14.94 - $18.3 $381,597 - $467,418	-25,542 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$15.45 - $18.12 $394,623 - $462,821	25,542 New	25,542 $398,000

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.